In this article:
Shares of Eli Lilly (LLY) are soaring after the pharmaceutical giant received regulatory approval in China for its GLP-1 weight-loss drug, Zepbound.
Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the approval and why China is a top market for pharmaceutical companies.
For more expert insight and the latest market action, click here to watch this full episode of Catalysts.
This post was written by Melanie Riehl